Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deprescribing Antimuscarinic OAB Medications in Parkinson Disease
NCT07627529Phase 4Not yet recruiting
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in overactive bladder (OAB), sponsored by Corporal Michael J. Crescenz VA Medical Center. Primary endpoints: Montreal Cognitive Assessment up to 46 weeks, Scales for Outcomes in Parkinson's Disease-Autonomic up to 46 weeks and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT07627529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627529.